Get the Stockscreener App
69.85
0.04%
-0.14
Belite Bio Inc Adr stock is traded at $69.85, with a volume of 31,064.
It is down -0.04% in the last 24 hours and up +36.66% over the past month.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
See More
Previous Close:
$69.71
Open:
$69.71
24h Volume:
31,064
Relative Volume:
0.72
Market Cap:
$2.13B
Revenue:
-
Net Income/Loss:
$-32.61M
P/E Ratio:
-91.88
EPS:
-0.7602
Net Cash Flow:
-
1W Performance:
-0.14%
1M Performance:
+36.66%
6M Performance:
+61.31%
1Y Performance:
+78.54%
1-Day Range:
$69.00
$70.30
1-Week Range:
$55.50
$70.90
52-Week Range:
$31.00
$70.90
Belite Bio Inc Adr Stock (BLTE) Company Profile
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Maxim Group | Buy |
| Jul-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-23 | Initiated | SVB Securities | Outperform |
| Aug-01-22 | Initiated | H.C. Wainwright | Buy |
| Jul-01-22 | Initiated | The Benchmark Company | Buy |
Belite Bio Inc Adr Stock (BLTE) Latest News
Belite Bio stock soars to all-time high of $70.4 amid robust growth - Investing.com
Belite Bio (NASDAQ:BLTE) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Belite Bio Offers New Warrant Opportunities to Investors - TipRanks
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds - ForexTV.com
Nike Inc (NKE-N) QuotePress Release - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Hits New 52-Week HighHere's What Happened - MarketBeat
Belite Bio (NASDAQ:BLTE) Trading Up 4%Should You Buy? - MarketBeat
Belite Bio (NASDAQ:BLTE) Hits New 12-Month HighHere's Why - MarketBeat
Belite Bio stock soars to all-time high of $56.62 By Investing.com - Investing.com UK
Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting - The Bakersfield Californian
First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial - Ophthalmology Times
Belite Bio (NASDAQ:BLTE) Sets New 12-Month HighStill a Buy? - MarketBeat
Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit - The Bakersfield Californian
Week in ReviewOctober 5, 2024 - Ophthalmology Times
Belite Bio (NASDAQ:BLTE) Hits New 1-Year High at $50.69 - MarketBeat
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - GlobeNewswire
Armistice Capital LLC Invests $6.76 Million in Belite Bio, Inc (NASDAQ:BLTE) - MarketBeat
International companies to host live webcasts at Deutsche - GlobeNewswire
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Down 5.1% in August - MarketBeat
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 - GlobeNewswire Inc.
Belite Bio (NASDAQ:BLTE) Rating Reiterated by HC Wainwright - Defense World
Belite Bio shares hold buy rating, steady target on trial progress - Investing.com
Belite Bio's (BLTE) Buy Rating Reiterated at HC Wainwright - MarketBeat
Belite Bio Announces First Patient Dosed in Phase 2/3 - GlobeNewswire
Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease - StockTitan
Belite Bio Welcomes New Chief Medical Officer - TipRanks
Belite Bio to Participate in Three Upcoming Investor Conferences - StockTitan
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Down 9.6% in August - MarketBeat
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer - ForexTV.com
Belite Bio (NASDAQ:BLTE) Sees Large Volume Increase - MarketBeat
Short Interest in Belite Bio, Inc (NASDAQ:BLTE) Expands By 10.7% - MarketBeat
Belite Bio (NASDAQ:BLTE) Trading Down 1.8% - MarketBeat
HC Wainwright Analysts Decrease Earnings Estimates for Belite Bio, Inc (NASDAQ:BLTE) - Defense World
FY2024 EPS Estimates for Belite Bio, Inc Lowered by Analyst (NASDAQ:BLTE) - Defense World
Golden Ocean Group (NASDAQ:GOGL) Downgraded to Sell at StockNews.com - Defense World
Abtech (OTCMKTS:ABHD) Shares Cross Above 50 Day Moving Average of $1.08 - Defense World
Cambian Group (LON:CMBN) Stock Price Crosses Below Two Hundred Day Moving Average of $192.40 - Defense World
Leerink Partnrs Equities Analysts Cut Earnings Estimates for Belite Bio, Inc (NASDAQ:BLTE) - Defense World
Price T Rowe Associates Inc. MD Purchases 357 Shares of National Bankshares, Inc. (NASDAQ:NKSH) - Defense World
Q3 2024 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Reduced by HC Wainwright - Defense World
Barnes & Noble Education (NYSE:BNED) Shares Pass Above 50 Day Moving Average of $7.94 - Defense World
QRG Capital Management Inc. Has $244,000 Holdings in Qifu Technology, Inc. (NASDAQ:QFIN) - Defense World
California State Teachers Retirement System Cuts Position in F&G Annuities & Life, Inc. (NYSE:FG) - Defense World
California State Teachers Retirement System Cuts Stake in Cassava Sciences, Inc. (NASDAQ:SAVA) - Defense World
Contrasting Priority Technology (NASDAQ:PRTH) and Swvl (NASDAQ:SWVL) - Defense World
Belite Bio, Inc to Post Q1 2025 Earnings of ($0.29) Per Share, HC Wainwright Forecasts (NASDAQ:BLTE) - MarketBeat
AstroNova, Inc. (NASDAQ:ALOT) Short Interest Down 44.4% in July - Defense World
Belite Bio (NASDAQ:BLTE) Receives “Buy” Rating from Benchmark - Defense World
Chardan Capital Research Analysts Raise Earnings Estimates for Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Q3 2024 EPS Estimates for Sun Life Financial Inc. Increased by National Bank Financial (TSE:SLF) - Defense World
QRG Capital Management Inc. Sells 8,711 Shares of Vipshop Holdings Limited (NYSE:VIPS) - Defense World
Belite Bio Inc Adr Stock (BLTE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):